Who Owns Sandoz?

As an independent company since 2023, Sandoz has established its own ESG framework. The company conducted a Double Materiality Assessment (DMA) in 2024 based on the European Sustainability Reporting Standards (ESRS) and has submitted greenhouse gas reduction targets to the Science Based Targets initiative (SBTi) for validation.

Sandoz reached approximately one billion patients in 2025, including an estimated 0.2 billion through active pharmaceutical ingredient (API) sales. The company's generics and biosimilars provide substantial global healthcare savings by offering affordable alternatives to branded medicines. Generics typically cost 80 to 90 percent less than their originator equivalents.

The company maintains sustainable manufacturing practices across its global production network. Sandoz implements environmental management systems and resource efficiency programs to minimize waste, energy consumption, and water usage in pharmaceutical manufacturing. The new Slovenia biosimilar hub and the Toulouse facility acquired from Just-Evotec Biologics are designed with modern environmental standards.

Sandoz conducts bioequivalence studies and clinical trials following international guidelines, ensuring patient safety, informed consent, and scientific integrity. The company works with suppliers who meet strict quality, environmental, and social standards for pharmaceutical ingredients and packaging materials.

As a publicly traded company on the SIX Swiss Exchange, Sandoz maintains corporate governance practices with transparent reporting and stakeholder engagement. The company published its first integrated annual report as an independent entity in 2024.

Sandoz received a Communique Award in 2024 in the Excellence in Corporate Communications category for successfully launching as the Independent Global Leader in Generic and Biosimilar Medicines. The award acknowledged the company's communication strategy during the spin-off from Novartis.

Sandoz is consistently recognized as the global and European market leader in generic and biosimilar medicines by industry analysts and pharmaceutical publications. The company's biosimilar business has been noted by the Center for Biosimilars and other industry organizations for its 17 consecutive quarters of growth.

No other independently verified awards specific to the Sandoz brand have been publicly documented beyond the Communique Award and market leadership recognition.

In July 2025, Sandoz Inc. issued a voluntary nationwide recall of several lots of Cefazolin for Injection, USP, 1 gram per vial, due to product mispackaging. Some vials were incorrectly labeled as Penicillin G Potassium for Injection, USP. The FDA announced the recall on July 14, 2025. Sandoz reported that it had not received any adverse events related to the mispackaging. The recalled products were distributed nationwide to wholesalers and distributors between December 4, 2024 and May 15, 2025. The recall was resolved through product recovery and corrective actions.

No other major controversies, regulatory actions, or lawsuits have been associated with Sandoz as an independent company. The company operates in a highly regulated industry and maintains compliance with FDA, EMA, and other regulatory body requirements across its manufacturing network.

The broader generic pharmaceutical industry faces ongoing pricing pressure and patent litigation. Sandoz navigates these challenges as part of its normal business operations, launching generic and biosimilar products following patent expirations and regulatory approvals.